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Reversible Lansoprazole-Induced
Interstitial Lung Disease Showing
Improvement after Drug Cessation
Lansoprazole is an acid proton-pump inhibiting drug that is used for the treat-
ment of duodenal or gastric ulcers, H. pylori infection, gastroesophageal reflux
disease or Zollinger-Ellison syndrome. Although lansoprazole is well known for its
gastrointestinal and dermatologic adverse effects, mild pulmonary symptoms are
also known to develop from taking this drug. There have been no reports about
lansoprazole-induced interstitial lung disease. We report here a case of lansopra-
zole-induced interstitial lung disease that developed in a 66-year-old man.
ansoprazole is an acid proton-pump inhibitor that is similar to omepra-
zole. It is used to treat duodenal or gastric ulcers, H. pylori infection,
gastroesophageal reflux disease (GERD) or Zollinger-Ellison syndrome.
Common adverse effects of lansoprazole are diarrhea, abdominal pain, skin rash
and/or itching. Information from U.S. National Library of Medicine warns that this
drug can on rare occasion cause cough or cold-like symptoms. The pathophysiological
mechanisms of lansoprazole-related pulmonary symptoms are not yet understood. In
particular, there are no known reports regarding lansoprazole-induced interstitial lung
diseases. We report here a case of interstitial lung disease (ILD) induced by oral
administration of lansoprazole, which showed a pattern of nonspecific interstitial
pneumonia (NSIP) as detected from a video-assisted thoracoscopic lung biopsy. We
believe that this is the first report of a case of pathologically proven lansoprazole-
induced ILD for which a surgical lung biopsy was performed.
CASE REPORT
The patient was a 66-year-old man without a smoking history. The patient had been
previously healthy until he was diagnosed with GERD a month prior, and began
treatment with lansoprazole. He had a history of working at a dusty place several
weeks before hospitalization, where he did not experience any respiratory symptoms.
However, a few days after initiation of lansoprazole treatment, cough and dyspnea
developed along with a febrile sense. After suffering from a progressively aggravating
cough and dyspnea for a month, the patient visited our hospital. 
Vital signs of the patient were stable and the laboratory studies including eosinophil
count were all in the normal ranges. An initial chest radiograph showed diffuse
ground-glass opacities in both lungs with upper lobe predominance, and we diagnosed
differentiated diffuse interstitial lung disease or interstitial pneumonia, such as
Pneumocystis carinii pneumoniae pneumonia (Fig. 1A). High-resolution computed
tomographic scans (HRCT) showed focal areas of diffuse ground-glass opacity in both
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Llungs with upper lung predominance, similar to those of
the plain radiographs (Figs. 1B, C). The patient was
hospitalized for further evaluation and treatment. A
transbronchial lung biopsy was performed, and the
histopathological result was acute lung injury with marked
type II pneumocyte hyperplasia, interstitial edema and
interstitial infiltration of lymphocytes. After only one day
of symptomatic treatment, both the clinical symptoms and
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Fig. 1. Lansoprazole-induced interstitial lung disease. 
A. Posteroanterior chest radiograph shows diffuse ground-glass
opacities in both lungs, which are predominant in upper lung zones.
B, C. Axial (B) and coronal (C) reconstruction high-resolution CT
images show areas of diffuse ground-glass opacity in both lungs with
upper lung predominance, similar to those seen in chest radiograph
(A). 
D. Histopathological specimen shows mixed interstitial infiltration of
lymphocytes and plasma cells, suggestive of nonspecific interstitial
pneumonia pattern. Note active hyperplasia of type II pneumocytes
(arrows) and Massons’ body (arrowheads).
E. Follow-up high resolution CT image shows markedly improved
opacities in both lungs. Faint areas of ground-glass opacity still
remain.
CD
Echest radiographic findings rapidly improved. Considering
his recent history of working at a dusty place, we thought
that the clinical, radiologic, and histopathological findings
represented hypersensitivity pneumonitis and we decided
to start prednisolone therapy (30 mg/day). However, on
the third day of prednisolone therapy, the patient
complained of sudden aggravation of dyspnea. Blood gas
analysis showed hypoxemia (SaO2 80% on room air), and
the chest radiographic findings showed aggravation of
diffuse bilateral infiltration. We performed a video-assisted
thoracoscopic lung biopsy to decide on further treatment
planning. The specimen showed a NSIP pattern with
frequent Masson’s bodies, active type II pneumocyte
hyperplasia and mixed interstitial inflammation without
hyaline membrane formation (Fig. 1D). The next day
following the operation, the respiratory symptoms and
chest radiographic findings all improved spontaneously,
which was difficult to explain.
It was difficult to explain the cause of the sudden
aggravation of symptoms and the imaging findings during
the hospitalization of the patient. Therefore, we carefully
reexamined the clinical course of the patient during the
hospitalization. It was noted that the patient stopped
taking lansoprazole immediately after admission in
preparation for the transbronchial lung biopsy, and he
restarted taking the drug along with prednisolone after the
biopsy. The patient again stopped taking lansoprazole
prior to the thoracoscopic lung biopsy. Such a temporal
relationship between the ingestion of lansoprazole and the
worsening of symptoms led us to conclude that the
symptomatic, radiological, and histopathological findings in
the patient actually represented a drug-induced interstitial
disease. Therefore, we stopped giving lansoprazole to the
patient and restarted prednisolone therapy. The clinical
symptoms and the pulmonary opacities on the follow-up
chest radiographs progressively improved. The follow-up
HRCT scans performed two days after the restart of
prednisolone therapy showed a marked improvement of
the ground glass opacities in both lungs (Fig. 1E).
DISCUSSION
Drug induced interstitial lung disease (DI-ILD) shows
various clinicoradiographical findings that range from non-
symptomatic infiltration to severe acute respiratory distress
syndrome (ARDS). For example, amiodarone or
methotrexate treatment may lead to nonspecific interstitial
pneumonia (NSIP), treatment with bleomycin, nitrofuran-
toin or sulfasalazine to acute organizing pneumonia
(alternatively called bronchiolitis obliterans organizing
pneumonia [BOOP]), and treatment with nonsteroidal
antiinflammatory drugs NSAIDs (nonsteroidal antinflam-
matory drugs) or some antibiotics to acute eosinophilic
pneumonia. These manifestations can lead to the clinicora-
diographically gas-exchange pattern of ARDS (1, 4).
Drug induced interstitial lung disease may present
several hours to several weeks after the introduction of the
causative drug. The clinical findings of DI-ILD include very
nonspecific symptoms such as a nonproductive cough,
dyspnea and fever, or crackles upon auscultation. The
laboratory results can show a range of findings from
normal to eosinophilia and/or leukocytosis (2). The
radiological findings of DI-ILD are also highly variable (3).
Although it is not pathognomic, the radiological findings
are sometimes very suggestive for certain types of DI-ILD.
Invasive diagnostic examinations (bronchoalveolar lavage,
transbronchial or thoracoscopic biopsy) are sometimes
needed to rule out other lung diseases, especially when the
medication history does not clearly meet the criteria of
drug-induced lung diseases (1). Among many types of DI-
ILD, NSIP is the second most common form of a
histopathological pattern, after usual interstitial pneumo-
nia. Clinically, NSIP usually starts as insidious dyspnea and
dry cough. Diffuse, heterogeneous ground-glass opacities
in both lungs, predominantly in the lower lobes are a
typical finding on chest radiography. An HRCT scan shows
focal or diffuse areas of ground-glass opacities with intersti-
tial fibrosis (4). In our case, despite the histopathological
findings consistent with NSIP, it was difficult to diagnose
our patient as having drug-induced NSIP, due to the
clinical and radiological differences when compared to
typical cases of the disease.
In fact, although a large number of drugs are known to
cause pulmonary complications, it is difficult to diagnosis
drug-induced lung disease (5). There are several reasons
that make such a diagnosis difficult. First, the clinical and
radiological findings are nonspecific and they can mimic
other pulmonary diseases (6). Many new drugs are being
developed and their adverse effects are have not been fully
characterized. Sometimes, both patients and clinicians do
not consider the adverse effects of a drug as a cause of
pulmonary symptoms. In some cases, there is no clear
temporal relationship between the initiation of a drug and
the onset of symptoms. 
To the best of our knowledge, this is the first description
of DI-ILD caused by lansoprazole. The diagnosis was made
by considering the radiological, histopathological and
clinical findings, including the close temporal relationship
between lansoprazole exposure and symptom severity.
Other possible causes were excluded due to a lack of a
temporal relationship between the symptoms and work
history or prednisolone therapy, and no other history of
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specific allergen exposure.
When there is diffuse interstitial lung disease with an
unknown etiology, it is important to remember that drugs
can be the cause of pulmonary symptoms and it is crucial
to take a careful patient history. If there is a recent history
of taking lansoprazole in a patient with clinical and
radiological findings of diffuse interstitial lung disease, we
recommend stopping the medication to see if there is
clinical and radiological improvement. That way, one can
avoid using invasive procedures to diagnose a lansopra-
zole-induced interstitial lung disease.
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